MA-OPTIKOS
12.9.2022 20:32:37 CEST | Business Wire | Press release
Optikos Corporation introduced three new products to its OpTest® and Meridian® lens and camera metrology product lines, developed to address the specific requirements for testing and image capture conditions in the field of automotive imaging.
Optikos has a long history of pioneering the development and commercialization of test equipment for the evaluation of lenses and cameras, including the OpTest® and LensCheck™ product families, widely regarded as the gold standard for assessing the image quality of lens assemblies; and the Meridian product line, for measuring the performance of an assembled camera. The Company is recognized not only for its comprehensive range of standard products, but also its readiness to customize hardware and software to suit a customer’s particular requirements such as those demanded in automotive imaging applications.
With two of its newest products, Optikos has extended its expertise in measuring the effects of stray light in lenses to camera assemblies—with the Meridian camera testing line now including products that serve as sources for measuring Veiling Glare Index (VGI) and Glare Spread Function (GSF).
VGI measurements are useful as a measure of diffuse irradiance on the image plane, and require a uniformly illuminated background field populated with one or more dark objects. The new Meridian VGI source is a customizable hemispherical integrating sphere into which light traps of various sizes may be fitted; and enables the customer to specify the sizes and locations of the light traps according to the characteristics of the camera assemblies to be tested. The system is illuminated using white LEDs, the intensity of which may be remotely controlled.
Glare Spread Function testing evaluates the severity of ghost reflections or other prominent stray light artifacts that form concentrated irradiation patterns. The new Meridian Sol-55 projector addresses this need with a modular design, and features interchangeable object aperture drawers for controlling the angular extent of the projected target, and an aperture wheel that controls the numerical aperture of the illumination through the object aperture. “The unique design avoids overfilling the lens under test and creating a secondary source of stray light from adjacent scattering surfaces; while illumination is provided by a high intensity white LED which can be remotely controlled for high dynamic range measurements,” said David Imrie, Optikos Chief Technology Officer.
Meridian Sol-55 projectors are designed to be flexibly mounted at pre-determined field points with respect to the device-under-test in rigid assemblies that form a Meridian Sunfield system. They are distinguished from Meridian Starfield assemblies of Static Target Projectors (STPs) used in image quality (MTF) testing of cameras.
In addition to stray light, temperature extremes pose a significant challenge for image sensor performance in automotive cameras. Optikos has been testing lenses across a range of temperatures in its IQ Lab™ Optical Testing Service since 2017, and first productized this process for testing lenses up to 150mm with its Thermal Module TM-1150 system.
The new TC-1065 is a thermal chamber used for lens testing that extends the maximum size of lenses that may be tested over a range of temperatures on a LensCheck system, complementing the smaller TC-1050 and TC-1010 products also available in the product line. In order to optimize the thermal performance, the thermal chamber is generally sized to match the dimensions of the lenses with which it will be used.
Optikos will be exhibiting at AutoSens Brussels 2022 on October 12-14th. To learn more about Optikos solutions for automotive imaging, see contact details below.
About Optikos
The Optical Engineering Experts®—Optikos provides leading-edge applications of optical technology to organizations worldwide. For customers who require optical testing and image quality assessment of lens and camera systems, we offer an advanced line of standard and custom metrology products as well as in-house IQ Lab™ Optical Testing Services. We offer product development services that include a broad range of engineering, contract manufacturing, and assembly capabilities. Our broad skill set, including optics, mechanics, electronics, automation, and software systems, enables us to quickly understand our customers' unique technical requirements and provide a flexible and scalable resource. Applications range from medical devices and diagnostics to aerial imaging, defense, automotive cameras, and well beyond.
For more information, visit optikos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005764/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
